Reviva Pharmaceuticals’ (RVPH) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a report issued on Tuesday morning,Benzinga reports. The firm currently has a $3.00 target price on the stock.

Reviva Pharmaceuticals Stock Down 1.8%

Shares of Reviva Pharmaceuticals stock opened at $0.80 on Tuesday. The stock’s fifty day moving average is $0.80 and its two-hundred day moving average is $1.33. Reviva Pharmaceuticals has a 52 week low of $0.49 and a 52 week high of $4.28. The company has a market capitalization of $37.39 million, a PE ratio of -0.72 and a beta of 0.11.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its earnings results on Thursday, May 15th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. As a group, research analysts anticipate that Reviva Pharmaceuticals will post -0.97 earnings per share for the current year.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. bought a new stake in shares of Reviva Pharmaceuticals during the fourth quarter valued at approximately $25,000. Cornerstone Select Advisors LLC bought a new stake in Reviva Pharmaceuticals during the 4th quarter valued at $32,000. XTX Topco Ltd purchased a new stake in shares of Reviva Pharmaceuticals in the 4th quarter worth $45,000. Tower Research Capital LLC TRC grew its position in shares of Reviva Pharmaceuticals by 848.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock worth $48,000 after buying an additional 23,953 shares in the last quarter. Finally, Ameriprise Financial Inc. purchased a new position in shares of Reviva Pharmaceuticals during the fourth quarter valued at $84,000. 63.18% of the stock is currently owned by institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.